POTS Adrenergic Ab (CIHR Aims #1&2)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT02673996, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Calgary
- Trial code
- NCT02673996
- Record updated
- 5 May 2026
- Original description
Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.Read full original descriptionShow less
The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)
Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.
Inclusion: Patients who have been previously diagnosed with POTS; Control subjects (patients not diagnosed with POTS); Age between 18 - 60 years; Males and Females (Give that >80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects); Able and willing to provide consent.
Exclusion: Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing; Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule; Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication; Smokers; Overt cause for postural tachycardia, i.e., acute dehydration; Highly trained athletes; Subjects with somatization or severe anxiety symptoms will be excluded; Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent; Unable to give informed consent.